Across the cohort of 862 patients with metastatic disease, the BRCA2 mutation rate was 5.6%; the rate was 5.0% across the POSH cohort as a whole (excluding dnMBC patients).22 The reason for such a large proportion of dnMBC cases having a BRCA2 mutation is unclear; it is possible that a family history of breast and ovarian cancer in BRCA2 mutation carriers meant that they were more vigilant regarding symptoms of metastatic disease. The gene discussed is BRCA2; the disease is ovarian cancer.